Better Buy: CRISPR Therapeutics vs. Intellia
These two gene-editing stocks have a lot going for them. Let's consider pipelines, partnerships, and profits to make a choice.
Editors' Picks
Sturm, Ruger Feeling the Effects of Desperate Rivals
While demand has picked up, heavy promotional activity in the industry remains a headwind.
Repligen Signals Gene Therapy Strength With 2019 Earnings Report
Guidance for 2020 appears to have spooked investors, but the bioprocess leader is on a solid long-term trajectory.
McDonald's Serving Up Fast-Food-Scented Candles
The world's biggest restaurant chain's newest product lets consumers enjoy the smell of a Quarter Pounder without the calories.
Recent articles
Will Bitcoin Ever Be a Serious Alternative to Gold and Stocks?
Experts say that bitcoin will either become a value store comparable to gold or die trying. Here's how far it would have to climb to reach that goal.
Zillow Pursues Brokerage Licenses That It Swears It Doesn't Want
The online real estate site keeps downplaying this potentially industry-shaking move.
Trillion-Dollar Foes: Does Amazon Web Services Reign Supreme in the Cloud Business?
Amazon's AWS could be outpaced by rivals and end up losing market share in the cloud.
The Canadian Marijuana Industry Has a Surprising $1 Billion Problem
If you thought things couldn't get worse for pot stocks, think again.
This Social Security Statistic Is Shocking
And it's a huge indication that countless seniors are making a very big mistake when claiming benefits.
Is Gilead Sciences Stock a Buy?
Gilead Sciences has drawn attention to itself with a possible coronavirus treatment -- but that isn’t the main reason to invest in the company.
5 References That Should Be on Your List to Land the Job
Select your professional references carefully.
Why Zscaler Needs More Cloud Cybersecurity
After better-than-expected fiscal second-quarter results, the company's stock price dropped by more than 10%, but its valuation remains high.
600 Million Reasons Why This Oil Stock Believes It Could Be a Big Winner in 2020 and Beyond
Marathon Oil thinks it can continue generating and returning a gusher of free cash flow to its investors.
5 Ways to Make Your Money Work for You
Why let your money sit around, goofing off, doing little for you, when those dollars could get jobs and bring home some additional dollars?
Can Kylie Jenner Beautify Coty's Bottom Line?
The cosmetics company looks to appeal to Gen Z buyers with a celebrity brand acquisition.
Is Tanger Factory Outlet Centers Stock a Buy?
This may be one of the most attractive risk-reward investments available today.
Millennials' Top 3 Financial Concerns This Year -- and How to Handle Them
Younger Americans are far from worry-free when it comes to money. Here's what's on their minds.
Better Buy: Editas Medicine vs. Intellia
Which of these two small-cap gene-editing stocks is a better investment?
China Challenges Can't Conceal e.l.f. Beauty's Makeover
The cosmetics company seems to be gaining after cutting loose from brick-and-mortar.
3 Biotech Stocks That Soared This Week: Are They Buys?
Can these high-flying biotech stocks keep up their sizzling momentum?
Did the Trump Tax Cuts Help Amy Klobuchar?
The presidential candidate paid more in tax in 2018, but her family also earned more income.
A Big Month Ahead for the FDA and Bristol-Myers Squibb
Success for the Celgene merger rests heavily on new drug approvals the U.S. Food and Drug Administration could deliver in March.
3 Asset Allocation Rules for Retirement
Here's how to manage your investments during your senior years.
Domino's Fortressing Strategy Still Risky Despite Comps Beat
The pizza joint benefited from third-party food delivery apps battling one another.